Skip to content

VitusCare raises ₹30 crore Series B to expand dialysis network and AI tools

·StartupReader editorial desk· 1 min readReviewed by our editors
FUNDING. ₹30 crore raised by VitusCare, dialysis network and AI tools. Hybrid model combines clinical services with technology; Focus on scaling both physical and digital healthcare assets.

The funding will support the growth of its physical healthcare operations while advancing digital capabilities for patient care and workflow optimization.

The investment highlights a strategy that combines clinical services with technology, a model gaining traction in India’s healthtech sector. Unlike startups focused solely on software, VitusCare’s approach—balancing direct healthcare delivery with AI integration—may appeal to investors looking for measurable impact beyond digital-only solutions.

Details on the investors or valuation remain undisclosed, leaving open questions about the round’s strategic backers. The company’s prior funding history is also not publicly available, but the focus on scaling both physical and digital assets suggests a deliberate effort to bridge gaps in healthcare delivery.

The round comes amid broader trends in Indian startups, where hybrid models—merging infrastructure with technology—are increasingly attracting funding. Whether VitusCare’s AI tools will eventually be offered as standalone products or remain embedded within its clinical operations remains to be seen. Updates on its expansion plans and AI deployment will be key to tracking its progress.

Sources: business-standard.com

“The round reflects investor interest in healthtech models that integrate physical infrastructure with AI-driven solutions.”
— StartupReader
ShareLinkedInXWhatsApp

One of the funding rounds reported in the week of 16–22 November 2026. See every round that week or just the Indian ones.

Read the original reporting

The outlets below did the original reporting.

Related briefs

This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.